MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company engaged in developing and commercializing innovative therapies and drug-delivery devices aimed at addressing significant unmet needs in endocrine disorders and rare pulmonary diseases.

As per US Dailies Report published on ‘MNKD’ on Mar 16, 2026, Kalkine provided an ‘Buy’ stance on the stock at USD 2.77 based on fundamental analysis and the stock price has now moved up by ~ 45.13% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale:

Despite the sharp rally following the ralinepag DPI collaboration update with United Therapeutics, MannKind continues to face elevated execution and commercialization uncertainties, as the program remains in early-stage development with upcoming non-clinical and Phase 1 studies still ahead. The company’s financial upside is currently tied to milestone payments and royalty potential rather than direct commercialization control, while regulatory approvals for ralinepag DPI across targeted indications remain uncertain. Additionally, the stock remains significantly lower on a year-to-date basis, reflecting broader concerns around sustainability of growth, dependence on partnership-driven revenues, and the long timeline required before the program could contribute meaningfully to earnings visibility.

Share Price Chart

Conclusion

Following the sharp post-announcement surge, early-stage development risks, partnership-dependent revenue visibility, and the extended timeline requirement for potential commercialization, a "Sell" is recommendation on MannKind Corporation (NASDAQ: MNKD) has been given at the current market price of USD 4.02 as on 06 May,2026 at 8:05 am PDT.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 06 May 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.